Pharsight

1. List of Izba drug patents

Application	Filing Date	Opposition Party	Legal Status
EP15202422A	2018-02-12	actrevo GmbH	Granted and Under Opposition
EP15202422A	2018-02-09	ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.	Granted and Under Opposition
EP15202422A	2018-02-09	Generics [UK] Limited (trading as Mylan)	Granted and Under Opposition
EP15202422A	2018-02-07	Bausch & Lomb Incorporated	Granted and Under Opposition
EP15202422A	2018-02-01	Instone, Terry/Appleyard Lees IP LLP/Read, Howard	Granted and Under Opposition
EP12193597A	2018-01-26	Alfred E. Tiefenbacher (GmbH & Co. KG)	Granted and Under Opposition
EP12193597A	2018-01-26	Generics [UK] Limited (trading as Mylan)	Granted and Under Opposition
EP09722278A	2016-02-29	Generics [UK] Limited (trading as Mylan)	Granted and Under Opposition
EP09722278A	2016-02-16	Alfred E. Tiefenbacher (GmbH & Co. KG)	Granted and Under Opposition
EP09722278A	2016-02-12	Pohlman, Sandra M.	Granted and Under Opposition

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9144561	NOVARTIS	Pharmaceutical compositions having desirable bioavailability	Mar, 2029 (5 years from now)
US8754123	NOVARTIS	Pharmaceutical compositions having desirable bioavailability	May, 2029 (5 years from now)
US8178582	NOVARTIS	Pharmaceutical compositions having desirable bioavailability	Oct, 2029 (6 years from now)
US8722735	NOVARTIS	Pharmaceutical compositions having desirable bioavailability	Oct, 2029 (6 years from now)

Do you want to check out IZBA patents from before 2022?

Market Authorisation Date: 15 May, 2014

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.00003	30 Dec, 2015	1		10 Oct, 2029	Extinguished

Strength	Dosage	Availability
0.003%	SOLUTION/DROPS;OPHTHALMIC	Discontinued

United States

European Union

Denmark

Spain

Japan

Hong Kong

Germany

China

Australia

Korea, Republic of

Canada

Uruguay

Chile

Portugal

Russia

Poland

Slovenia

Mexico

Argentina

Brazil

South Africa

Hungary

Taiwan

Application	Filing Date	Opposition Party	Legal Status
EP07842925A	2016-03-17	Pohlman, Sandra M.	Patent maintained as amended
EP07842914A	2012-08-02	Pohlman, Sandra M.	Patent maintained as amended
EP07842914A	2012-08-02	ALLERGAN, INC.	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US8268299	March, 2017	FWD Entered	Alcon Research, Ltd.	Argentum Pharmaceuticals LLC
US8268299	July, 2013	Terminated-Settled	ALCON RESEARCH, LTD.	Apotex Corp.
US8323630	July, 2013	Terminated-Settled	ALCON RESEARCH, LTD.	Apotex Corp.
US8388941	July, 2013	Terminated-Settled	Alcon Research, Ltd.	Apotex Corp.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8388941	NOVARTIS	Self preserved aqueous pharmaceutical compositions	Sep, 2027 (4 years from now)
US8323630	NOVARTIS	Self-preserved aqueous pharmaceutical compositions	Sep, 2027 (4 years from now)
US8268299	NOVARTIS	Self preserved aqueous pharmaceutical compositions	Oct, 2029 (6 years from now)